These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Neurotransmitters and neuropeptides in schizophrenia]. Toru M; Ichikawa H Tanpakushitsu Kakusan Koso; 1984 Dec; 29(14):1838-54. PubMed ID: 6085408 [No Abstract] [Full Text] [Related]
4. [Neurotransmitters in Huntington chorea (review)]. Barkhatova VP; Larskiĭ EG Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):444-50. PubMed ID: 2581405 [No Abstract] [Full Text] [Related]
5. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Johansson JO; Larson G; Andersson M; Elmgren A; Hynsjö L; Lindahl A; Lundberg PA; Isaksson OG; Lindstedt S; Bengtsson BA Neuroendocrinology; 1995 Jan; 61(1):57-66. PubMed ID: 7537355 [TBL] [Abstract][Full Text] [Related]
6. Determination of neurochemically important compounds in physiological samples using HPLC. Anderson GM; Young JG Schizophr Bull; 1982; 8(2):333-48. PubMed ID: 6180473 [No Abstract] [Full Text] [Related]
7. Difference in neurotransmitter metabolism in frontotemporal-lobe contusion and diffuse cerebral contusion. van Woerkom TC; Teelken AW; Minderhous JM Lancet; 1977 Apr; 1(8015):812-3. PubMed ID: 66617 [No Abstract] [Full Text] [Related]
11. [Neurotransmitters and degenerative diseases in the central nervous system]. Nakamura S Nihon Ronen Igakkai Zasshi; 1986 Jan; 23(1):11-6. PubMed ID: 2423726 [No Abstract] [Full Text] [Related]
12. Amine metabolites in the cerebrospinal fluid as a measure of central neurotransmitter function: methodological aspects. Bertilsson L; Asberg M Adv Biochem Psychopharmacol; 1984; 39():27-34. PubMed ID: 6205559 [No Abstract] [Full Text] [Related]
13. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity? Scheinin M Med Biol; 1985; 63(1):1-17. PubMed ID: 2582215 [TBL] [Abstract][Full Text] [Related]
15. Parallel variation of homovanillic acid and 5-hydroxyindoleacetic acid in ventricular cerebrospinal fluid of man. Inagawa T; Mori S; Yoshimoto H; Ishikawa S; Uozumi T Hiroshima J Med Sci; 1976 Sep; 25(2-3):79-87. PubMed ID: 1026667 [No Abstract] [Full Text] [Related]
16. 5-Hydroxyindoleacetic acid and homovanillic acid in human cerebrospinal fluid below partial and complete spinal subarachnoid block. Massarotti M; Roccella P; Toffano G Eur Neurol; 1978; 17(3):174-80. PubMed ID: 658062 [TBL] [Abstract][Full Text] [Related]
17. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375 [TBL] [Abstract][Full Text] [Related]
18. Neurotransmitters, precursors and metabolites in spinal cord and brain of Lewis rats with EAE. Honegger CG; Isler H Prog Clin Biol Res; 1984; 146():131-8. PubMed ID: 6201886 [No Abstract] [Full Text] [Related]
19. Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomic failure. Polinsky RJ; Brown RT; Burns RS; Harvey-White J; Kopin IJ J Neurol Neurosurg Psychiatry; 1988 Jul; 51(7):914-9. PubMed ID: 2462617 [TBL] [Abstract][Full Text] [Related]
20. Clinical application of the probenecid test for measurement of monoamine turnover in the CNS. Faull KF; Kraemer HC; Barchas JD; Berger PA Biol Psychiatry; 1981 Sep; 16(9):879-99. PubMed ID: 6170352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]